Traws Pharma Management
Management criteria checks 0/4
Traws Pharma's CEO is Iain Dukes, appointed in Mar 2025, has a tenure of less than a year. directly owns 1.05% of the company’s shares, worth $91.08K. The average tenure of the management team and the board of directors is 1.7 years and 1.7 years respectively.
Key information
Iain Dukes
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 1.0% |
| Management average tenure | 1.7yrs |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate
Mar 09
Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation
Apr 22Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans
Jul 27Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?
Mar 21Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth
Dec 06CEO
Iain Dukes (67 yo)
Dr. Iain D. Dukes, M.A. D.Phil. & Ph D., is Director of NeRRe Therapeutics Ltd. Dr. Iain D. Dukes serves as President at Kartos Therapeutics, Inc. He is Secretary & Director of Traws Pharma, Inc. from Apri...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Medical Officer of Oncology | 2.3yrs | US$478.44k | 0% $ 0 | |
| CEO, Secretary & Director | less than a year | no data | 1.05% $ 91.1k | |
| Chief Financial Officer | less than a year | no data | no data | |
| COO & Director | 1.7yrs | no data | 1.05% $ 91.1k | |
| Chief Medical Officer | 1.7yrs | no data | no data | |
| Chief Scientific Officer of Virology | 1.7yrs | no data | 0.31% $ 26.6k |
Experienced Management: TRAW's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Secretary & Director | 1.7yrs | no data | 1.05% $ 91.1k | |
| COO & Director | 1.7yrs | no data | 1.05% $ 91.1k | |
| Director | 1.7yrs | US$796.02k | 1.23% $ 107.2k | |
| Independent Chairman | 9.6yrs | US$226.49k | 0.00010% $ 8.7 | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 5.7yrs | US$117.99k | 0.0017% $ 147.2 | |
| Independent Director | 3yrs | US$103.99k | 0% $ 0 |
Experienced Board: TRAW's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/31 16:14 |
| End of Day Share Price | 2025/12/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Traws Pharma, Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Thomas Cooper | Edison Investment Research |
| Etzer Darout | Guggenheim Securities, LLC |
| Michael Schmidt | Guggenheim Securities, LLC |